Showing results (361-370 of 369) with videos related to
Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 369 results.
The Lancet. Diabetes & Endocrinology|July 11, 2024
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M Apperloo, Brendon L Neuen, Robert A Fletcher, et al.Circulation|April 7, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-AnalysisSiddharth M Patel, Yu Mi Kang, KyungAh Im, et al.Circulation|July 17, 2020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFAlice M Jackson, Pooja Dewan, Inder S Anand, et al.Diabetes Care|June 27, 2013
Pathways to quality inpatient management of hyperglycemia and diabetes: a call to actionBoris Draznin, Janice Gilden, Sherita H Golden, et al.Journal of Diabetes and Its Complications|December 19, 2021
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseasesYehuda Handelsman, John E Anderson, George L Bakris, et al.JACC. Heart Failure|March 4, 2022
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER TrialScott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.JAMA|March 29, 2020
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without DiabetesMark C Petrie, Subodh Verma, Kieran F Docherty, et al.The New England Journal of Medicine|September 20, 2019
Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J V McMurray, Scott D Solomon, Silvio E Inzucchi, et al.The New England Journal of Medicine|August 26, 2022
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D Solomon, John J V McMurray, Brian Claggett, et al.Pageof 37